Prosecution Insights
Prosecution Insights
5 pending office actions • 5 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (20%) |
| §102 only | 1 (20%) |
| §112 only | 2 (40%) |
| Multi-statute (no §101) | 1 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GRIZER, CASSANDRA SENN | 1 | 60.0% | +26.7% |
| EDGINGTONGIORDANO, FRANCESCA | 1 | 71.8% | +30.6% |
| STAVROU, CONSTANTINA E | 1 | 44.2% | +36.3% |
| ROGERS, ERIC JASON | 1 | 57.3% | +30.6% |
| KATAKAM, SUDHAKAR | 1 | 74.7% | +23.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18270917 | FULLY HUMAN BROAD-SPECTRUM NEUTRALIZING ANTIBODY 76E1 AGAINST CORONAVIRUS, AND USE THEREOF | GRIZER, CASSANDRA SENN | 23d |
| 18009713 | CHIMERIC ANTIGEN RECEPTOR AND USE THEREOF | EDGINGTONGIORDANO, FRANCESCA | 85d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17290767 | APPLICATION OF ECM1 IN PREVENTION AND/OR TREATMENT OF LIVER FIBROSIS-RELATED DISEASES | KATAKAM, SUDHAKAR | 52d overdue |
| 17292296 | USE OF ECM1 GENE-KNOCKOUT MOUSE IN SCREENING OF ANTI-HEPATIC FIBROSIS DRUG | ROGERS, ERIC JASON | 8d |
| 18270917 | FULLY HUMAN BROAD-SPECTRUM NEUTRALIZING ANTIBODY 76E1 AGAINST CORONAVIRUS, AND USE THEREOF | GRIZER, CASSANDRA SENN | 23d |
| 18009713 | CHIMERIC ANTIGEN RECEPTOR AND USE THEREOF | EDGINGTONGIORDANO, FRANCESCA | 85d |
| 18248443 | Method for Inducing Differentiated Cells Into Pluripotent Endoderm Stem Cells and Application Thereof | STAVROU, CONSTANTINA E | — |
| Art Unit | Apps |
|---|---|
| 1672 | 1 |
| 1643 | 1 |
| 1632 | 1 |
| 1638 | 1 |
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18270917 | FULLY HUMAN BROAD-SPECTRUM NEUTRALIZING ANTIBODY 76E1 AGAINST CORONAVIRUS, AND USE THEREOF | GRIZER, CASSANDRA SENN | 1672 | §102§112 | Non-Final OA | 23d | Pending | Jul 05, 2023 |
| 18009713 | CHIMERIC ANTIGEN RECEPTOR AND USE THEREOF | EDGINGTONGIORDANO, FRANCESCA | 1643 | §101§102§103Other | Non-Final OA | 85d | Pending | Jun 05, 2023 |
| 18248443 | Method for Inducing Differentiated Cells Into Pluripotent Endoderm Stem Cells and Application Thereof | STAVROU, CONSTANTINA E | 1632 | §102 | Final Rejection | — | Pending | Apr 10, 2023 |
| 17292296 | USE OF ECM1 GENE-KNOCKOUT MOUSE IN SCREENING OF ANTI-HEPATIC FIBROSIS DRUG | ROGERS, ERIC JASON | 1638 | §112 | Non-Final OA | 8d | Pending | Sep 15, 2021 |
| 17290767 | APPLICATION OF ECM1 IN PREVENTION AND/OR TREATMENT OF LIVER FIBROSIS-RELATED DISEASES | KATAKAM, SUDHAKAR | 1658 | §112 | Final Rejection | 52d overdue | Pending | Jul 27, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial